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It is well known that cutaneous melanoma is characterized by
an early onset of metastatic spread as even very thin primary
lesions are able to generate metastasis, and metastatic dis-
ease may occur in the absence of a detectable primary le-
sion. Deciphering the genetic alterations and the signalling
pathways involved in the neoplastic transformation of mel-
anocytes will provide the basis for identifying new drugs
targeting the molecules involved and which could overcome
melanoma cell resistance to cytotoxic compounds.
Though many genes have been reported to be involved
in human melanoma formation, their specific role and inter-
action and the underlying mechanisms of action in mel-
anocyte transformation remain elusive. In most of the pre-
vious studies, the authors’ attention was focussed on a
single pathway whose alteration might result in neoplasia.
For example, whereas the role of p16 inactivation in mel-
anoma is well established, that of p53 pathway disruption is
not. Because of the central role played by the p53 pathway
in tumor pathogenesis through the control of genomic sta-
bility, cell cycle arrest, induction of apoptosis, and tran-
scriptional activity on genes involved in tumor progression
(Milyavsky et al, 2005), the potential contribution of p53 in
melanoma needs clarification.
In fact, the frequency of p53 mutations detected in me-
lanoma has been generally reported to be lower than in
other tumor types. The most common mechanism deter-
mining alterations in the p53 pathway in melanoma is rep-
resented by the homozygous deletion of the alternative
reading frame (ARF) and p16 genes as the result of
CDKN2A locus injury. Since ARF preserves the functional
activity of p53, whereas p16 is more relevant for retino-
blastoma (RB), deletions involving CDKN2A exons can the-
oretically disrupt both regulatory pathways.
But if homozygous deletions of exons 1a and 1b (or 1a
and 2) of CDKN2A affect both p16 and ARF, the effects of
point mutations occurring in exon 2 are less clear, since few
of them have been functionally characterized for their effect
on ARF, thus leaving doubts on the real need of p53 path-
way inactivation.
Nonetheless, concomitant mutations in TP53 and p16
genes have been reported in some melanoma cell lines and,
in a recent study, we found TP53 mutations either concom-
itant or alternative with respect to those of the CDKN2A
locus, the latter always being associated with BRAF muta-
tions. Of note, this mutational profile is preferentially found
in poorly surviving patients (Daniotti et al, 2004).
In this issue of the Journal, Yang et al (2005) have re-
assessed the potential effect of inactivating the two master
regulatory pathways RB and p53 in human melanoma for-
mation by analyzing data on gene alterations in a large col-
lection of cell lines. The authors come to the conclusion that
disruption of both pathways can be detected in the large
majority (70%–80%) of the melanoma studied, thus indi-
cating that concomitant injury of both pathways might rep-
resent the basis of human melanocyte transformation.
The authors consider mutations in the CDKN2A, CDK4,
and TP53 genes in a set of cell lines and by making a pooled
analysis of their data with those previously reported by our
group (Daniotti et al, 2004) (75 cell lines in total), show con-
current p16 and p53 mutations, CDKN2A exon 2 deletions
in conjunction with p53 mutations, positive association be-
tween CDK4 and p53 mutations and negative association
between exon 1b deletions and p53 mutations. Importantly,
all these combinations of genetic alterations can potentially
lead to the dysfunction of both RB and p53 pathways,
though this was not directly tested in functional assays. The
authors, however, adopted a novel predictive model to as-
sess CDKN2A exon 2 point mutations, using a program that
determines the degree of disruption and provides a qual-
itative description of its functional impact. The analysis was
performed not only on the mutations reported in their study,
but on 117 CDKN2A exon 2 point mutations detected in
different tumors, according to a list compiled by Ruas and
Peters (1998). Results show a greater impact on p16 than
on ARF, thus obtaining by predictive modelling an interpre-
tation supporting coincident alterations in p53, or deletions
in exon 1b, to achieve dual inactivation of RB and p53
pathways. These data add to the recurrent inactivation pat-
terns reported above.
Further support of the Yang et al viewpoint comes from
the functional disruption of the RB locus, reported to occur
in melanoma cell lines (Bartkova et al, 1996), a finding in
keeping with the lack of RB expression shown in melanoma
specimens (Korabiowska et al, 2001).
Our own analysis of RB protein expression in cell lines
harboring wild-type p16 and CDK4 genes showed that in
three of eight cases studied RB was not detectable by
immunoblotting. Notably, of the four of 41 tested cell lines
expressing the p16 protein, three lines obtained from dif-
ferent lesions of a single patient, all harboring a mutated
p53 and wild-type CDKN2A genes and detectable p16 and
ARF proteins, lack RB protein expression (M. Rodolfo, un-
published results). Whether this can be ascribed to RB gene
mutations remains to be determined.
Thus, the study of Yang et al reinforces the role of the p53
pathway in melanoma; mutations at the TP53 gene are
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confirmed in 25% of melanomas, as also reported in other
studies. Several other findings suggest a role for p53 in
melanoma: (a) animal studies showing that p53 and BRAF
pathways interact genetically to produce melanoma (Patton
et al, 2005), (b) human melanocytes in which both RB and
p53 pathways are inactivated along with induction of hTERT
constitutive activity, are prone to transformation by activat-
ed RAS and show invasive growth in human skin trans-
planted in mice (Chudnovsky et al, 2005), and (c) the
analysis of TP53 polymorphism at codon 72 indicates p53
gene involvement in melanoma risk (Shen et al, 2003).
As a note of caution, we should mention that since stud-
ies have been performed on melanoma cell lines and mu-
tated TP53 is known to facilitate the in vitro establishment of
cell lines from tumor specimens, an overestimation of the
reported frequencies of TP53 alterations in these studies
cannot be ruled out. What about the 15%–20% melanomas
not showing these patterns of genetic alterations? An ob-
vious answer is that since p16 is generally not expressed,
these samples may require more detailed analysis in the
p53 gene or, alternatively, the assessment of ARF methyl-
ation status.
Having established the merging of RB and p53 master-
pathways alterations as a crucial step in cutaneous mel-
anocyte transformation, what’s the next step in the defini-
tion of the underlying genetic mechanism? We believe that a
clearer—though more complex—definition will come from
the integration of data from the analysis of the other path-
ways that have been involved in melanoma, such as the
PI3K–PTEN–AKT pathway, and BRAF/NRAS oncogenes.
This analysis might result in the identification of molecularly
defined genetic signatures of melanoma groups with differ-
ent biological and clinical behavior. A concerted effort of
research groups interested in genetic characterization of
melanoma cell lines and samples aimed to pool data would
certainly be worthwhile and would likely result in a signif-
icant molecular classification of melanoma subtypes (Bitt-
ner et al, 2000; Pavey et al, 2004). Results of these studies
could eventually lead to the identification of new molecular
targets for the long awaited more effective therapy of met-
astatic melanoma.
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